Short Interest in Ascendis Pharma A/S (NASDAQ:ASND) Grows By 13.9%

Ascendis Pharma A/S (NASDAQ:ASND) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 3,350,000 shares, a growth of 13.9% from the March 15th total of 2,940,000 shares. Based on an average daily trading volume, of 375,400 shares, the days-to-cover ratio is presently 8.9 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. GAMMA Investing LLC acquired a new position in Ascendis Pharma A/S during the 4th quarter worth $25,000. SkyView Investment Advisors LLC acquired a new position in Ascendis Pharma A/S during the 2nd quarter worth $66,000. US Bancorp DE lifted its holdings in Ascendis Pharma A/S by 35.2% during the 4th quarter. US Bancorp DE now owns 284 shares of the biotechnology company’s stock worth $36,000 after buying an additional 74 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in Ascendis Pharma A/S by 90.4% during the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after buying an additional 151 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in Ascendis Pharma A/S by 37.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after buying an additional 91 shares in the last quarter.

Analysts Set New Price Targets

ASND has been the topic of several analyst reports. Wedbush lifted their target price on Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an “outperform” rating in a research note on Thursday, February 8th. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Monday, December 25th. Wells Fargo & Company lifted their target price on Ascendis Pharma A/S from $196.00 to $260.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. Jefferies Financial Group started coverage on Ascendis Pharma A/S in a research note on Wednesday, December 20th. They issued a “buy” rating and a $150.00 price target on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $173.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, April 1st. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.25.

Ascendis Pharma A/S Stock Down 0.7 %

Shares of Ascendis Pharma A/S stock traded down $1.06 during midday trading on Tuesday, hitting $144.17. The company’s stock had a trading volume of 154,198 shares, compared to its average volume of 374,875. Ascendis Pharma A/S has a 1-year low of $66.03 and a 1-year high of $161.00. The firm has a market capitalization of $8.39 billion, a P/E ratio of -15.65 and a beta of 0.50. The stock has a 50-day simple moving average of $149.10 and a 200-day simple moving average of $123.28.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.15) by $0.49. The company had revenue of $148.62 million for the quarter, compared to the consensus estimate of $97.02 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. As a group, sell-side analysts predict that Ascendis Pharma A/S will post -4.18 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.